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What Is So Bad About a Hemoglobin Level of 12
to 13 g/dL for Chronic Kidney Disease Patients
Anyway?
Anatole Besarab, Stanley Frinak, and Jerry Yee
Randomized controlled trials (RCTs) clearly indicate a possible cardiovascular morbidity and mortality
risk when deliberately targeting a normal hemoglobin (Hb) concentration of 13 to 15 g/dL. By contrast,
observational studies point to greater hospitalization and mortality at Hb levels ,11 g/dL. There are no
direct data to help us determine where, within this broad range, the optimal Hb lies. In RCTs and observational studies, significant confounding from the interrelationships of anemia and epoetin resistance
occurs in patients with a serious illness. Patients with comorbidities such as malnutrition and
inflammatory processes are more resistant to epoetin and, invariably, require greater cumulative epoetin doses. The effect of a higher erythropoiesis-stimulating agent (ESA) dose on increasing mortality
has been noted repeatedly in post hoc analyses of RCTs. It is therefore too simplistic to solely attribute
the outcomes achieved in RCTs to ‘‘target Hb.’’ We discuss various mechanisms for potential harm at
higher Hb levels as opposed to those that may be obtained from higher epoetin doses. For the individual patient, the therapeutic decision should center on what Hb is most appropriate at a ‘‘safe’’ ESA dose.
Consequently, an Hb of 12 to 13 g/dL may be totally appropriate in some patient populations.
Q 2009 by the National Kidney Foundation, Inc. All rights reserved.
Index Words: Anemia; Chronic kidney disease; Erythropoiesis-stimulating agent; Iron deficiency

‘‘I

t was the best of times. It was the worst of
times.’’ So begins the opening of Dickens’
A Tale of Two Cities. Whether those times were
good or bad depended on the observer’s perspective. The same might be said about maintenance of hemoglobin (Hb) levels in the 12 to 13
g/dL range in chronic kidney disease (CKD)
patients at varying stages of disease. Randomized controlled trials (RCTs) indicate that there
is a strong trend for increased risk of death or
adverse composite outcomes with erythropoiesis-stimulating agent (ESA) treatment in kidney disease to Hb targets higher than those
currently recommended. However, the RCT
results stand in stark contrast to findings
from large observational, population-based
studies that continue to show the association
of low and not ‘‘high’’ hemoglobin with
adverse outcomes. As a result, polarized positions have been taken. Some believe that any
hemoglobin .13 g/dL is harmful and that
this level must be avoided. This position has
also been taken by the United States Food
and Drug Administration who simply will
not permit any study examining anemia management to exceed an Hb of 13 g/dL while
advocating for a target Hb range of 10 to 12
g/dL. Others contend that there is no additional risk as long as the dose producing the
Hb of 13 or greater is ‘‘low.’’ The purpose of

this review was to summarize the conflicting
results and provide a balanced perspective regarding the target Hb range.

Target Hemoglobin: The History
When epoetin alfa was first approved for use
in 1989, the recommended treatment was for
partial correction of anemia to an Hb of 9 to
10 g/dL, with the primary objective of avoiding transfusion,1 despite the fact that initial
clinical trials targeted a higher Hb range
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with mean maintenance Hb values .11 g/dL.
2,3
Because of a variety of external pressures,
chiefly reimbursement, the main question
was not the target Hb, but rather the quantity
of ESA, its frequency,4,5 and its route6 that provided the highest mean Hb among dialysis patients. Two years after the introduction of
epoetin in the United States, Hb levels averaged less than 10 g/dL and the average dose
less than 8,500 U/wk.7 Six years later when
the first National Kidney Foundation (NKF)
Kidney Disease Outcomes Quality Initiative
(KDOQI) anemia guidelines were released,8
the mean Hb had increased to nearly 11 g/dL
(with a proportional increase in epoetin alfa
dose to nearly 16,500 U/wk) and, most
recently, to a mean of approximately 12 g/dL
with an average weekly epoetin dose of
22,000 U. Although the Hb target was widened by the updated NKF KDOQI anemia
guidelines to 11 to 13 g/dL,9 there was
coincident adoption by the Centers for Medicare and Medicaid Services (CMS) of the clinical performance measure (CPM) quality

indicator of achieving an Hb of 11 g/dL or
greater in 80% of patients.10
As shown in Figure 1, the target Hb adopted in Canada11 and worldwide tended to parallel those of the United States. However,
European Best Practices Guidelines12 had the
same lower but no upper limit on Hb. The
Australian-New Zealand (Caring for Australians with Renal Impairment) guidelines for
its upper limit depended on the presence or
absence of cardiovascular disease.13 In the
United Kingdom, the lower limit was less at
10 g/dL. Until the pure red cell aplasia scare
of the early 2000,14,15 the most common route
of administration outside the United States
was subcutaneous because of the increased
cost-effectiveness of this route.16,17
These guidelines for higher Hb evolved as
evidence accumulated, and a better understanding was reached regarding the benefits
of correcting Hb. These were chiefly in quality
of life3 and persistent observational findings of
lower mortality and hospitalization at higher
as compared with lower achieved Hb values.18

KDOQI
2007 update
11-12 g/dL
(not intentionally
> 13 g/dL)
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> 11 g/dL
(upper limit
individualized)

EBPG
> 11 g/dL
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not defined)
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> 11 g/dL CVD
12-14 g/dL no CVD

10.5-12.5 g/dL
10-12 g/dL in
children < 2yr

CARI
11-12 g/dL CVD
12-14 g/dL no CVD

Figure 1. Anemia management guidelines and target Hb. Since 1997, a number of clinical guidelines for
the management of anemia have been developed. Guidelines have evolved as evidence has accumulated. Improved understanding of the benefits of correcting Hb in specific patient groups has also
been attained (eg, patients with comorbid conditions such as CVD and diabetes). CVD, cardiovascular
disease; DOQI, dialysis outcomes quality initiative; EBPG, European Best Practice Guidelines; CSN,
Canadian Society of Nephrology, CARI, Caring for Australians with Renal Impairment: KDOQI, Kidney
Disease Outcomes Quality Initiative; UK NICE, United Kingdom National Institute for Clinical Excellence.9-13
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However, the interest in normalizing Hb to
13 g/dL or greater was initially dampened by
the first large randomized controlled trial
(RCT) of Hb normalization in hemodialysis
patients (Normal Hematocrit Cardiac Trial
[NHCT]) that found a trend toward increased
mortality risk with treatment to an Hct target
of 42%.19 Subsequently, 4 randomized controlled trials19-22 in ESRD dialysis-dependent
patients and eight trials in non–dialysisdependent CKD patients compared treatment
with 2 different Hb targets,23-30 one target
being 12 to 14 g/dL and the other target several grams lower. Most of the studies found
improved quality of life at the higher Hb targets. However, none showed a significant improvement in mortality or cardiovascular
endpoints. Rather, it has been the inverse; targeting higher hemoglobin may produce harm.

Informative Clinical Trials
Figure 2 depicts the major clinical trials that
have been conducted over the past 2 decades.

133

The earliest trials (dotted box) compared
a level of anemia (usually ,9 g/dL) with
a moderate level of correction (usually 10.512.5 g/dL). However, the most common
mean Hb target was between 11 and 12 g/dL
(solid box); RCTs since 1998 have mostly compared 2 different levels of correction, a lower
range of 9 to 11 (dashed lines) with a higher
range .12 and usually .13 g/dL.
Early meta-analyses of RCTs of kidney
disease patients treated with ESAs that suggested that Hb targets .13 g/dL compared
with ,12 g/dL were associated with higher
risk of mortality31 were dominated by the
NHCT. This study of hemodialysis patients
had a sample size of over 620 patients in
each of the 2 groups19 and did not show a statistically significant increase in death rate
when the study was stopped for safety reasons (increased morbidity from vascular
access thrombosis in the higher 13-15 g/dL
group), but it did not show benefit either. In
addition, in the Canadian study on cardiac

Figure 2. Clinical trials on anemia management. The dashed box includes trials before 1998, which were
generally small (ie, N , 100) and compared an Hb level ,9 g/dL to an Hb level of 11 to 12 g/dL, depicted
by the solid vertical box (incomplete correction of anemia). After 1998, larger trials compared effects of
moderate levels of correction (range between dashed vertical lines) and more complete anemia correction (Hb .12 g/dL). (Adapted from NKF-K/DOQI Clinical Practice Guidelines for Anemia in Chronic Kidney Disease.9)
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remodeling in incident patients, increased
stroke was found in the higher target (13.514.5 g/dL) compared with the lower target
(9.5-11.5 g/dL). All other studies in the metaanalysis were by themselves grossly underpowered to evaluate mortality or morbidity
risk.
However, the potential ‘‘danger’’ of higher
Hb levels was rekindled with the November
2006 publication of 2 large studies, the Cardiovascular risk Reduction by Early Anemia
Treatment with Epoetin Beta (CREATE) trial23
and the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial,24
in nondialysis CKD patients. Both studies
found trends toward increased mortality risk
and for other adverse outcomes as well.
In the CHOIR study by Singh et al,24 a composite endpoint assessing multiple events was
used. These included death, hospitalization,
hospitalization for congestive heart failure,
cerebrovascular accident, and residual renal
decline assessed as the need to initiate dialysis. Before the study was scheduled for completion, the ‘‘DSMB recommended.study be
terminated.even though neither the efficacy
or futility boundaries had been crossed,
because the conditional power of benefit for
the high-hemoglobin group by the scheduled
end of study was less than 5%.’’ When the final
data were collated and analyzed, the composite endpoint was significantly higher in the
group randomized to the higher Hb target of
13.3 g/dL compared with the group randomized to an Hb of 11.3 g/dL even though the
Hb target in the higher Hb group fell short
by 0.5 g/dL. None of the individual components of the composite including mortality
risk in these nondialysis kidney patients was
significantly different in the higher Hb target
group.
In the CREATE study,23 a composite of 8
cardiovascular events was used to assess hazard. This study was completed as designed,
with data collected for 2 more years after final
patient enrollment. A trend toward harm was
also noted in CREATE in the group targeted to
attain/maintain an Hb of 13.5 g/dL by early
epoetin beta therapy, but the hazard rate again
did not reach significance because the event
rate was only half that expected. The event
rate used to calculate the sample size for CRE-

ATE was based on data collected almost
a decade earlier in British Columbia, Canada,
and did not factor in the improvements in
care of CKD nondialysis patients that had
accrued in the previous decade. Thus, it, like
many other previous studies, was underpowered to evaluate mortality risk or a composite
endpoint measuring death, cardiovascular
events, or the need for renal replacement
therapy.
Despite the fact that both studies individually failed to show definitive proof of harm
because of unforeseen methodologic flaws,
the addition of these large studies allowed
the performance of a more powerful metaanalysis of the available studies totaling
5,000 patients. Such an analysis was reported by Phrommintikul et al32 in February
2007. Indeed, the 3 largest RCTs published,
the CHOIR (n ¼ 1,433),24 NHCT (n ¼
1,232),19 and CREATE (n ¼ 600)23 trials, all
found trends toward increased mortality
risk. The results of these 3 studies are consistent: an increase in all-cause mortality of about
20% at higher Hb targets is seen in each of the
3 studies but in none of them individually.
Only when all the studies are combined does
a statistically significant effect emerge. Although all 3 studies have design or execution
flaws, like all RCTs, and these have recently
been elucidated for the CHOIR and CREATE
trials,33 the consistent thread of evidence in
the direction of increased risk of death must
be taken seriously.34
Vascular access thrombosis also increases at
higher Hb levels,19,20 and blood pressure control often worsens. With this in mind and with
similar adverse findings reported from studies
of ESA treatment in cancer,35 the US Food and
Drug Administration took the dramatic step
of drastically increasing the warnings contained in labels for ESA drugs on March 9,
2007,36 in effect placing a ‘‘black box’’ warning
and narrowing the ‘‘recommended’’ Hb target
range to 10 to 12 g/dL.

Reflections on Observational Data
In contrast to the RCT, observational studies
have shown a totally different effect of Hb
levels on mortality. As stated previously, Hb
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Figure 3. Increasing erythropoietin alfa doses produce higher Hb levels. The relationship between administered erythropoietin dose and Hb is shown from 1995 to 2004. The mean achieved Hb of approximately 7,500 subjects, from annually derived Centers for Medicare and Medicaid Services data of the
Clinical Performance Measures anemia project, is shown from a 3-month interval of data collection
from months October through December (Adapted from Besarab A, Frankenfield D, Johnson C, et al:
Trends in anemia management in HD patients: Observations from the Centers for Medicare & Medicaid
(CMS) Clinical Performance Measures (CPM) Project. Presented at the American Society of Nephrology,
Nov 2007).

targets and the Hb achieved have evolved
since epoetin alfa was introduced in 1989.
As shown by the data from the CMS-CPM
project in Figure 3, Hb levels and epoetin
dose increased in parallel37 in the decade
from 1995 to 2004. In this decade, NKFDOQI guidelines put pressure on providers
to achieve an Hb .11 g/dL in 80% of patients
receiving maintenance hemodialysis. The
ratio of the change in epoetin alfa that produced a change in Hb, as noted by Figure 3,
was 100 U/kg/wk epoetin alfa per 11.0 g/
dL Hb change.
Large databases have been analyzed to
assess the consequences of raising the Hb level
during this period. Data from the USRDS have
repeatedly noted that higher Hb levels correlate with lower hospitalization rates, fewer
cardiovascular events, and better survival in
dialysis patients.38,39 Utilization of epoetin is
higher among for-profit dialysis facilities,
which frequently achieve higher mean Hb
levels than not-for-profit ones40 and achieve
higher Hb levels in their patients. In the forprofit, large dialysis organization, DaVita,
Regidor et al41 noted a lower mortality rate

among hemodialysis patients who maintained
hemoglobin levels between 12 and 13 g/dL as
opposed to lower Hb values. After adjustments for demographic and laboratory information in this study, a time-averaged
hemoglobin level of 12 to 12.9 g/dL was associated with approximately half the mortality
rate compared with a hemoglobin level of 10
to 10.4 g/dL. No adverse effect of Hb up to
a value of 13 g/dL was noted in this study, increasing only when Hb exceeded 13.5 g/dL. In
a similar vein, Szczech et al42 recently showed
by post hoc analysis of the CHOIR trial that
patients who achieved their target Hb had
better outcomes than those who did not.
Among subjects who achieved their randomized target, there was no discernible increased
risk associated with the higher Hb goal.
In assessing the results from these observational analyses, one must be aware of serious
confounding from the interrelationship of anemia and epoetin resistance with illness in
patients with CKD. Patients with comorbidities such as malnutrition and inflammatory
processes are more resistant to epoetin and
invariably require greater cumulative epoetin
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dose to achieve the target hemoglobin level.
The sickest patients rarely achieve target
hemoglobin levels and are the more likely to
die than healthier patients who achieve target
hemoglobin levels easily and persistently and
require much less epoetin in doing so.39,43
Therefore, the time-averaged hemoglobin
level may reflect both the targeted hemoglobin
level and the health of the patient.

Reconciliation of Discordant Results
It is important to realize that the health of the patient, the Hb targeted, the Hb level achieved,
and the dose of ESA are all interrelated. It is
not possible from the current literature to determine the relative importance of increased Hb itself as the primary cause of the increased risk of
death with targeting higher Hb levels. In fact,
a post hoc analysis of the Normal Hematocrit
Cardiac Trial, the largest randomized trial on
Hb target conducted to date among hemodialysis patients, found that the achieved Hct level to
normal was not associated with an increased
risk for death. As shown in Figure 4, in both
the high Hct target group and the lower target
groups, there was a trend toward an increased
risk for death with a lower achieved Hct. In the
more anemic group, the hazard decreased
smoothly with hematocrit reaching a nadir at

an Hct of 36 to 39 (Hb of 12-13 g/dL), whereas
in the higher hematocrit group, there was
a sharp discontinuity. Those who achieved
and maintained an Hct/Hb of 39%/13 g/dL
or greater did as well as those who spontaneously drifted beyond the prespecified Hct
limits of 27% to 33%. In this study, a post hoc
analysis of the higher Hct/Hb target group
showed that mortality was 60% lower in those
who responded well to epoetin compared with
those who did not.44
This effect of the achieved dose on mortality has repeatedly been found in post hoc analyses of the randomized clinical trials. The
Food and Drug Administration also showed
the influence of achieved dose in both the
NHCT and CHOIR as shown in Figure 5.45
Whatever the stated target hemoglobin of
a study that uses active therapy in both study
arms, the mean target Hb value will be harder
to achieve in the higher of the 2 arms. This
results from the presence of subjects in the
randomized population who are resistant to
the administered ESA, in whom it takes longer
to achieve the given goal (if at all). In clinical
practice, when hemoglobin targets are 12 g/
dL or less, these targets can be achieved
more frequently than if the targets are set
higher.

Hazard Function: Normal Hematocrit Trial (NHCT)
1.6
Anemic
1.4

Normal

1.2
1.0
0.8
0.6
0.4
0.2
0
< 27

27 - 29.9

30 - 32.9

33 - 35.9

36 - 38.9

39 - 41.9

42 - 44.9

≥ 45

Hematocrit (Hct) Range (%)

Figure 4. Hazard function (death or acute myocardial infarction [AMI]) derived from the Normal Hematocrit Trial.19 There is a monotonic decrease in hazard ratio in the anemic group as achieved Hct increases
from ,27% to an Hct of 39%, despite an Hct goal of 27% to 33%. By contrast, in the normal Hct group,
hazard function is increased in subjects who do not attain their Hct target, despite increasing amounts of
erythropoietin. In those who attain the target Hct .39%, the hazard is equal to or lower than in the highest 2 Hct subgroups of the anemic Hc’ group. The obvious question is what characteristics and therapy
differentiates those with Hct levels of 30% to 39% in the 2 groups to produce this increase in mortality.
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higher Hb target group. (B)
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from those in Normal Hematocrit Trial (NHCT) (panel A),
with Hb generally greater in
CHOIR than NCHT. A Ushaped mortality curve is
seen in the low Hb target
group, but the mortality
curve is descending in the
higher target group. (C)FDA
‘‘dynamic’’ analysis of relations between serious cardiovascular (CV) events,
prevailing Hb, and the rate
of change of the preceding
Hb in the Normal Hematocrit
Trial. These analyses show
the importance of prevailing
Hb and the rate of change of
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on CV event rates.
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In practice, the clinicians can also compromise on the dose being used and accept
a lower Hb (either voluntarily or when
proscribed by the third-party payer such as
CMS) for a given patient. If an Hb of 10.5 g/
dL is all that can be achieved at a dose of 450
U/kg/wk, a dose frequently cited as being indicative of resistance achieved (Fig 6),46 one
does not have to continuously increase the
ESA when the dose response beyond that is
flat (diminishing returns). This is not true in
an RCT in which dose is progressively ‘‘per
protocol’’ increased irrespective of response.
In Eschbach’s original report,46 there was
considerable interpatient variability in the
epoetin alfa dose required to maintain the
Hb/Hct level in the target range. In this phase
3 trial, the median dose required to maintain
an Hct level of 35% 6 3% in hemodialysis
patients was 75 U/kg intravenously 3 times
per week. A relatively broad range of required
doses from 12.5 to 525 U/kg intravenous/
dose was observed; however, 17% of patients
required doses $150 U/kg 3 times per week.
A decade and a half later, data from the
CMS-CPM for 2005 showed virtually the
same results from a national sample of
.7,500 individuals; 15% of all patients still
meet this definition of resistance by ESA

dose. This minority of patients receives more
than half of all of the epoetin administered.3
Finally, both the Food and Drug Administration45 and others have found a very complex relationship between cardiovascular
events/mortality and the Hb achieved and
the rate of change in Hb before the events. In
general, a U-shaped curve exists with a nadir
for each Hb stratum for no change in Hb,
with risk increasing as prevailing Hb
decreases from 13 to 10 g/dL. Of course,
ESA dose increases inversely with prevalent
Hb and, possibly, even more so as Hb falls
abruptly. Because a putative adverse effect of
epoetin dose has been posited by Cotter
et al,47 it is naive to solely ascribe enhanced
risk to ‘‘target’’ Hb in RCTs.

Potential Mechanisms of Harm
When examined carefully, the risk shown in the
higher Hb target groups of the clinical trials has
been related to thrombotic events, manifested
as vascular occlusion, myocardial events, cerebrovascular accidents, or deep vein thrombosis. A key unknown is the mechanism for
such a process. Fishbane and Besarab48
reviewed possible mechanisms recently. One
mechanism that focused on was thrombosis.

70
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Figure 6. Interpatient variability of
epoetin alfa dosing. In this phase 3
60
trial by Eschbach and colleagues,
USA CMS CPM data 2005,
the median dose required to maintain
national sample of > 7500
a Hct level of 35%63% in hemodialy50
patients
sis patients was 75 U/kg 3 times per
week intravenously. A relatively
40
Hyporesponsive patients consume
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53% of all epoetin alfa
12.5 - 525 U/kg bodyweight was re30
corded, and 17% of patients required
34% of all epoetin alfa used by
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that this distribution persists more
10
than a decade later. ‘‘Hyporesponsive’’ or epoetin alfa-resistant patients use the majority of the
0
50
100 150 200 250 300 350 400 > 500
agent.46 (Reprinted with permission
Erythropoietin dose (U/kg)
from Eschbach JW, Abdulhadi MH,
Browne JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease.
Result of a phase III multicenter clinical trial. Ann Intern Med 111:992–1000, 1989). The American College of Physicians is not responsible
for the accuracy of the translation.
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Effects of epoetin on platelets have been documented for over 2 decades. Epoetin transiently
quantitatively increases circulating platelets
and improves platelet function, effects associated with a return of the bleeding time toward
normal.49 However, a restoration toward ‘‘normal’’ Hb will increase viscosity and wall shear
stress on the vascular endothelium, which is
already abnormal in advanced CKD. Changes
in shear stress on endothelial cells are associated with the release of microparticles into
the circulation. Circulating microparticles are
associated with a variety of disorders characterized by coagulapathy (heparin-induced
thrombocytopenia, thrombotic thrombocytopenic purpura, paroxysmal nocturnal hemoglobinuria, sickle cell disease) as well as
vascular and cardiovascular diseases.50 Shed
membrane microparticles with procoagulant
potential are produced by human atherosclerotic plaques.51 The relationship between viscosity, shear rate, and Hb level is not linear.
Shear-induced apoptosis at a higher Hb level
could be a critical determinant of plaque
thrombogenicity after plaque rupture. Thus,
increased shear stress might produce endothelial injury or alter endothelial function increasing risk for thrombosis in some susceptible
patients and the risk related to elevated Hb
could be accentuated by hemodialysis-induced hemoconcentration.52 This may partially explain evidence from previous studies
of increased mortality risk among hemodialysis patients with larger interdialytic weight
gains.53
Another contributing mechanism might be
abnormal fibrin-clotting properties. In ESRD,
fibrin clots derived from patient plasma are
less permeable, compactible, and susceptible
to fibrinolysis than control clots. Scanning
electron microscopy reveals a greater fibrin
fiber density in clots from patients with
CKD than in clots of patients without
CKD.54 Interestingly, these fibrin structure
characteristics in ESRD patients are associated primarily with the inflammatory plasma
milieu rather than with the level of azotemia.
It is the inflamed patient who appears most
at risk for thrombosis during ESA therapy.
In a follow-up study of 39 patients with
such measurements of clot characteristics,
mortality was significantly associated with
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reduced clot permeability, prolonged lysis
time, faster fibrin protofibril formation,
thicker fibers, and increased fibrin clot
mass, suggesting that these unfavorable
altered clot properties may contribute to
increased CV mortality.
Recently, Dahl et al55 have proposed
a prominent role for iron deficiency in promoting thrombosis in patients on ESA therapy, the
so-called iron hypothesis. An analysis of
a large cohort of patients indeed confirmed
that higher platelet counts were associated
with lower iron stores and with higher prescribed epoetin dose.56 The argument is as follows. Dependence on ESA to raise Hb
produces functional or absolute iron deficiency. Thrombocytosis is common in iron
deficiency and resolves after iron repletion.
ESAs have long been known to increase platelet number,49 perhaps not only through an
effect on megakaryoctes57 but also through
this iron-deficiency pathway.58,59
Such relative thrombocytosis increases the
risk of thrombovascular events. Concurrent
provision of iron should minimize ESA-driven
thrombocytosis. Data from the Dialysis Patients Response to Intravenous (IV) Iron With
Elevated Ferritin (DRIVE) trial60 in hemodialysis patients in which there was iron administration even at ferritin levels .500 ng/mL
verifies this hypothesis. Platelet counts in intravenous iron-treated patients decreased by
29,000/mL, but were unchanged in patients
not treated with intravenous iron.55 Unfortunately, the major anemia trials that used
ESAs reported no detailed platelet data.
Lastly, relative iron deficiency has been proposed to enhance the thromboembolic rates
of ESA-treated oncology patients.61
Another mechanism for altered coagulation
may arise from altered platelet responses during ESA therapy independent of iron deficiency. Before the introduction of ESA, deep
vein thrombosis/pulmonary embolism was
exceedingly rare in anemic hemodialysis
patients.62 A decade after ESAs were introduced, such events began to occur with regularity63 with an age-adjusted risk ratio of .2.64
It is now known that recombinant erythropoietin increases platelet aggregability through
a tyrosine phosphorylation–signaling pathway65 and in fact has been used to increase
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coagulation in patients with alcoholic liver
disease.66 In addition, epoetin has the following independent effects on vessels via
increased endothelin-167: impaired endothelium-dependent nitric oxide–induced vasorelaxation,68 perturbed calcium homeostasis in
vascular smooth muscle cells,69 and enhanced
platelet serotonin release.70 These nonerythropoietic effects of ESA on platelet reactivity,
both directly and indirectly from iron deficiency, mandate that iron sufficiency is maintained at the lowest possible ESA dose to
achieve the desired Hb range in a given
patient. ‘‘Harm’’ from ‘‘nonhemoglobin’’
effects of ESAs may mask a benefit from
higher Hb levels.
Currently, little work has been performed
to differentiate the various ESAs from each
other in terms of these nonerythropoietic
effects. Some of the vascular effects of epoetin
develop only at supraphysiologic concentrations achieved with intravenous doses. A consistent change to the subcutaneous route or
use of agents that do not need high peak levels
but depend on prolonged residence time at
lower concentrations might reduce these risks
of thrombosis. However, no comparative data
are available.

Personal Position
We currently do not know the characteristics
of patients at risk for harm other than they
are ‘‘ill’’ from inflammatory processes, use
iron poorly because of reticuloendothelial
blockade, and require much higher doses of
epoetin than easily responsive patients in
whom the issue is one of exceeding Hb .12
at relatively low doses. In the former, there
is, in our opinion, definite harm from progressively increasing epoetin doses into the flat
part of the dose response curve where no
improvement in erythropoiesis can occur.
Such patients with kidney disease and atherosclerosis can have multiple areas of unstable
atherosclerotic plaque and/or ulcerations
that are vulnerable to increased viscosity associated sheer stress and platelet hyperaggregability even when Hb is only 11 g/dL or less.
In such patients, it is unwise to attempt to
attain the CPM goal of 11 g/dL. ESRD patients
may be particularly sensitive to volumetrically

induced Hct changes and/or viscosity/shear
stresses that occur over hours and not weeks
as occurs in normals.
In contrast, we have experienced difficulty
in maintaining Hb stability in highly ESAsensitive patients. This group exhibits upward
variability after minimal increases in ESA
dose. Patients who drift above 13 g/dL receiving ,3,000 U/wk frequently will drift below
11 g/dL over 3 months with only a 20% to
30% reduction in a weekly dose. It is extremely
difficult to maintain such patients in the
‘‘desired’’ range, and they do note the difference in vitality at lower as compared with
higher Hb levels.

Conclusion
There is nothing wrong with an Hb of 12 to 13
in the right patient treated with a low ESA
dose. By contrast, there is everything wrong
when administering a high ESA dose just to
attain an Hb of 11 g/dL. The target Hb and
ESA dose must be individualized.
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